Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.
Opdam M, van der Noort V, Kleijn M, Glas A, Mandjes I, Kleiterp S, Hilbers FS, Kruger DT, Bins AD, de Jong PC, Schiphorst PPJBM, van Dalen T, Flameling B, Rietbroek RC, Beeker A, van den Heiligenberg SM, Bakker SD, Wymenga ANM, Oving IM, Bijlsma RM, van Diest PJ, Vermorken JB, van Tinteren H, Linn SC. Opdam M, et al. Among authors: kleijn m. Breast Cancer Res Treat. 2022 Jul;194(2):265-278. doi: 10.1007/s10549-022-06618-z. Epub 2022 May 19. Breast Cancer Res Treat. 2022. PMID: 35587322 Free PMC article. Clinical Trial.
Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
Göker E, Hendriks MP, van Tilburg M, Barcaru A, Mittempergher L, van Egmond A, Kleijn M, Generali D; of the NBREaST II Investigators Group. Göker E, et al. Among authors: kleijn m. Eur J Cancer. 2022 May;167:92-102. doi: 10.1016/j.ejca.2022.03.003. Epub 2022 Apr 11. Eur J Cancer. 2022. PMID: 35421703 Free article.
Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study.
Noordhoek I, Bastiaannet E, de Glas NA, Scheepens J, Esserman LJ, Wesseling J, Scholten AN, Schröder CP, Elias SG, Kroep JR, Portielje JEA, Kleijn M, Liefers GJ. Noordhoek I, et al. Among authors: kleijn m. J Geriatr Oncol. 2022 Nov;13(8):1172-1177. doi: 10.1016/j.jgo.2022.07.006. Epub 2022 Jul 21. J Geriatr Oncol. 2022. PMID: 35871138 Free article.
58 results